Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Early Hum Dev. 2020 May 22;147:105078. doi: 10.1016/j.earlhumdev.2020.105078

Table 3.

Multiple linear regression models with significant results using average cytokine levels

Unadjusted β [95% CI] p-value R2 Adjusted β1 [95% CI] p-value R2 β1 [95% CI] p-value R2
NAPI MDV
  TNF-α −0.16 [−0.42, 0.12] 0.26 0.018 −0.11 [−0.35, 0.15] 0.41 0.087 −0.33 [−0.60, −0.06] 0.018 0.11
  TNF-α*PMA 0.03 [−0.02, 0.08] 0.3
  TNF-α*sex −0.04 [−0.74, 0.67] 0.92
  IL-1RA −0.42 [−0.70, −0.16] 0.002 0.13 −0.37 [−0.64, −0.08] 0.013 0.16 −0.61 [−1.05, −0.16] 0.008 0.18
  IL-1RA*PMA 0.02 [−0.03, 0.07] 0.38
  IL-1RA*sex 0.01 [−0.49, 0.52] 0.96
NAPI AO
  IL-6 0.09 [0.02, 0.15] 0.01 0.009 0.11 [0.03, 0.20] 0.011 0.068 1.29 [0.005, 2.52] 0.049 0.13
  IL-6*PMA −0.11 [−0.25, 0.02] 0.09
  IL-6*sex 0.49 [−1.31, 2.35] 0.59
  TNF-α −0.02 [−0.19, 0.15] 0.78 0.0006 0.01 [−0.17, 0.20] 0.88 0.054 0.22 [0.01, 0.42] 0.042 0.11
  TNF-α*PMA −0.03 [−0.07, 0.01] 0.13
  TNF-α*sex 0.15 [−0.39, 0.70] 0.58

Note.

1

Adjusted for length of stay. NAPI, Neurobehavioral Assessment of the Preterm Infant; MDV, motor development and vigor; AO, alertness/orientation; TNF-α, tumor necrosis factor-alpha; IL-1RA, interleukin-1 receptor antagonist; PMA, post-menstrual age; β = standardized regression coefficient; CI, confidence interval; R2 = variance explained by model.